They conjugated DOX and a T7 peptide that targets brain tumor cells by binding to the transferrin receptor (TfR), often overexpressed in glioblastoma [253] and brain capillary endothelial cells [254,255] to a poly-l-lysine dendrimer loaded with the pORF-hTRAIL plasmid. The gene discussed is TFRC; the disease is brain neoplasm.